No justification is available for having a particular threshold level of ldlcholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. Dec 17, 2008 apolipoproteins, cardiovascular risk and statin response in type 2 diabetes. Design of the collaborative atorvastatin diabetes study. This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. To describe baseline characteristics of patients in the collaborative atorvastatin diabetes study cards, a randomized. Baseline characteristics in the collaborative atorvastatin diabetes study cards in patients with type 2 diabetes. The aim of the collaborative atorvastatin diabetes. In the collaborative atorvastatin diabetes study cards, the effect of lipitor on cardiovascular disease cvd endpoints was assessed in 2838 subjects 94% white, 68% male, ages 4075 with type 2 diabetes based on who criteria, without prior history of cardiovascular disease and with ldl. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the collaborative atorvastatin diabetes study cards diabetologia, dec 2005 h. Action to control cardiovascular risk in diabetes eye study research group. Pdf effects of atorvastatin on kidney outcomes and. Statin use and risk of diabetes mellitus in postmenopausal. The aim of this study was to evaluate the effect of atorvastatin on lipid lowering, cardiovascular cv events, and adverse events in women compared with men in 6 clinical trials.
Pdf primary prevention of cardiovascular disease with. Based on the clinical cards data, the favourable cost effectiveness of atorvastatin 10mg in. Lipitor atorvastatin calcium clinical studies pfizer. The study received ethical approval both centrally and at each participating institution, and each patient gave written. Ofthe collaborative atorvastatin diabetes study cards inthe belgian population marbaix s1,vandenberghe h1,van gaal l2 1p. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study cards. Methods the collaborative atorvastatin diabetes study cards is a multicentre, randomized, placebocontrolled, doubleblind clinical trial of primary prevention of cardiovascular disease in patients with type 2 diabetes. In 2,627 participants without known vascular disease in the collaborative atorvastatin diabetes study, apob, apoai, ldlcholesterol ldlc and hdl. For the prevention of cardiovascular disease, statins are a firstline treatment. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of pre. Pdf baseline characteristics in the collaborative atorvastatin. Pdf design of the collaborative atorvastatin diabetes study. These guidelines are based on numerous trials showing a benefit for statin therapy both as primary and secondary prevention of cardiovascular disease and mortality 27. The primary endpoint, time to the first occurrence of acute coronary events, coronary revascularisation or stroke, was significantly reduced by 37% in patients treated with.
Atorvastatin was recently approved for the latter indication in france, based on the results of the collaborative atorvastatin diabetes study cards 2 3 4. An overview of cards collaborative atorvastatin diabetes study. The primary objective is to investigate whether treatment with the hydroxymethylglutaryl coenzyme a reductase inhibitor. The collaborative atorvastatin diabetes study cards randomized placebocontrolled trial. Patients with type 2 diabetes and no prior cvd n 2,838.
An overview of cards collaborative atorvastatin diabetes study primary prevention of cardiovascular disease with atorvastatin in type 2. Apr 23, 2019 lipitor passes into breast milk and could harm a nursing baby. Analysis of efficacy and safety in patients aged 65. Atorvastatin reduced cv events even in low ldl dm patients. Colhoun hm, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, charltonmenys v, demicco da, fuller jh. In the collaborative atorvastatin diabetes study cards, the effect of atorvastatin calcium on cardiovascular disease cvd endpoints was assessed in 2838 subjects 94% white, 68% male, ages 40 to 75 with type 2 diabetes based on who criteria, without prior history of cardiovascular disease and with ldl. The collaborative atorvastatin diabetes study cards was a doubleblind, randomized, placebocontrolled, multicenter trial of atorvastatin 10 mgday for the primary prevention of cvd in type 2 diabetes. Trials like the collaborative atorvastatin diabetes study cards, proved beyond doubt that patients with type 2 diabetes and other risk factors for cvd should be treated with a statin, apparently disregarding their. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of preexisting vascular disease and who had only. The collaborative atorvastatin diabetes study cards recently established that treatment of type 2 diabetic patients with atorvastatin 10 mg. American diabetes association indications for statins in. An analysis from the collaborative atorvastatin diabetes study cards author links open overlay panel helen m.
Population 56 963 patients with diabetes initiating statin use from 2005 to 2008. Cvd 46, but the costeffectiveness of statins in the primary prevention of cvd in people with diabetes has not been assessed adequately. We examined whether atorvastatin affects diabetic kidney disease and whether the effect of atorvastatin on cardiovascular disease cvd varies by kidney status in patients with diabetes. Ironically, there is a very compelling clinical trial showing the value of one statin, lipitor atorvastatin, in type 2 diabetes the collaborative atorvastatin diabetes study known as cards. Reduce the risk of mi, stroke, revascularization procedures, and angina in patients without chd, but with multiple risk factors reduce the risk of mi and stroke in patients with type 2 diabetes without chd, but with multiple risk factors. The primary objective is to investigate whether treatment with the hydroxymethylglutaryl coenzyme a reductase inhibitor, atorvastatin, reduces the incidence of major cardiovascular events. Abstract background there are few data on the role of lipid lowering in the primary prevention of coronary heart disease chd in diabetic. The goal of the collaborative atorvastatin diabetes study cards trial was to determine the effectiveness of the lipidlowering agent atorvastatin in reducing cardiovascular events and death among diabetic patients with at least one heart disease risk factor, but without elevated cholesterol.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes cards overview 1 a multicenter randomized placebo controlled trial to determine hard outcomes of atorvastatin 10mg vs. Ezetimibe added to statin therapy after acute coronary. The safety and tolerability of atorvastatin 10 mg in the collaborative. Aug 21, 2004 atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high ldlcholesterol. Atorvastatin reduced major cardiovascular disease events in. Cards is designed to show if lowering cholesterol with atorvastatin in type 2 diabetics without cv disease reduces the risk of cv events cards the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Atorvastatin, sold under the brand name lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipid levels. Effects of atorvastatin on kidney outcomes and cardiovascular. In the collaborative atorvastatin diabetes study cards, the effect of lipitor atorvastatin calcium on cardiovascular disease cvd endpoints was assessed in 2838. This enzyme catalyzes the conversion of hmgcoa to mevalonate, an early and ratelimiting step in cholesterol biosynthesis. One would not want patients to stop statins as a result of this study, as statins are particularly effective in preventing cardiovascular disease in diabetics.
Collaborative atorvastatin diabetes study american. The collaborative atorvastatin diabetes study cards, comparing treatment with atorvastatin lipitor, pfizer inc with placebo in 2800 patients with type 2 diabetes but without overt heart. Aug 01, 2004 read baseline characteristics in the collaborative atorvastatin diabetes study cards in patients with type 2 diabetes, diabetic medicine on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Dec 01, 2007 read stroke prediction and stroke prevention with atorvastatin in the collaborative atorvastatin diabetes study cards, diabetic medicine on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. This is not a complete list of side effects and others may occur. Comparison of rosuvastatin and atorvastatin for lipid. Collaborative atorvastatin diabetes study cards 2838 primary prevention patients no ascvd with type 2 diabetes at least 1 other cv risk factor such as smoking, hypertension, retinopathy, or microalbuminuria ldlc levels. The collaborative atorvastatin diabetes study cards. Costeffectiveness of primary prevention of cardiovascular. Lipitor atorvastatin calcium tablets description lipitor atorvastatin calcium is a synthetic lipidlowering agent.
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes. To estimate the costeffectiveness of atorvastatin 10 mg compared with no treatment for the primary prevention of. May 18, 2006 cards is designed to show if lowering cholesterol with atorvastatin in type 2 diabetics without cv disease reduces the risk of cv events cards the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. This study aimed to estimate the cost effectiveness in the belgian setting of atorvastatin 10 mg compared with no treatment for the primary prevention of cv. The forecasts of this model have been shown to closely predict events in other diabetic populations such as patients participating in the collaborative atorvastatin diabetes study 19 and in the proactive study. The objective of this study was to evaluate the safety and tolerability of atorvastatin 10 mg compared with placebo in 2,838 patients with type 2 diabetes and no history of coronary heart disease who were enrolled in the collaborative atorvastatin diabetes study cards. Main outcome measures we determined the proportions of realworld. Contribution to cards collaborative atorvastatin diabetes study. Collaborative atorvastatin diabetes study cards and fol lowed for 3. The collaborative atorvastatin diabetes study cards recently investigated the effects of lipid lowering with statin therapy specifically in patients with type 2 diabetes. Statin use and risk of diabetes mellitus in postmenopausal women in the womens health initiative. In the collaborative atorvastatin diabetes study cards, the effect of lipitor atorvastatin calcium on cardiovascular disease cvd endpoints was assessed in 2838 5. Colhoun hm, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, thomason mj, mackness mi, charltonmenys v, fuller jh and cards investigators.
Colhoun hm1, betteridge dj, durrington pn, hitman ga, neil ha, livingstone sj, thomason mj, mackness mi, charltonmenys v, fuller jh. A landmark lipitor study of patients with type 2 diabetes. Design of the collaborative atorvastatin diabetes study cards. Openurl1crossref2pubmed3web of science4 q in patients with type 2 diabetes mellitus, is atorvastatin better than. Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes, but no signs or symptoms of preexisting vascular disease and who had only average or below average cholesterol levels. Atorvastatin reduced major cardiovascular disease events. Breastfeeding while taking lipitor is not recommended. Major cv events occurred in 3,083 of 30,000 men 10. Cards, 2004 trial summary pdf trial summary a randomised clinical trial investigating the effect of atorvastatin versus placebo in patients with type 2 diabetes without high concentrations of ldlcholesterol and at least one of the following. Feb 11, 2011 the american diabetes association has recommended using statins a class of drug used to lower cholesterol levels for patients with type 2 diabetes.
An analysis from the collaborative atorvastatin diabetes study cards. He helped design the study, seek funding from diabetes uk, nhs and pfizer and had close involvement in the management and success of the study. Design a populationbased analysis with linked register data. Baseline characteristics in the collaborative atorvastatin. Collaborative atorvastatin diabetes study listed as cards. Hitman was copi and rotating chair of the academically led cards study in type 2 diabetes 5. We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 6575 years at randomization with 1,709 younger patients in the collaborative atorvastatin diabetes study cards. Study cards was to assess the effectiveness of 10 mg of atorvastatin daily versus placebo. Oct 30, 2008 controversy surrounds whether the ratio of apolipoprotein b apob to apolipoprotein ai apoai is the best lipoprotein discriminator of chd risk in nondiabetic populations, but the issue has never been investigated in type 2 diabetes. Safety of atorvastatin in the collaborative atorvastatin diabetes study cards the safety and efficacy of sta the safety and efficacy of statins for cvd prevention is well established, yet some physicians have concerns about the longterm safety of this class. Rapid emergence of effect of atorvastatin on cardiovascular. Atorvastatin calcium tablet is an inhibitor of hmgcoa reductase statin indicated as an adjunct therapy to diet to. Renal effects of atorvastatin and rosuvastatin in patients. The aim of the collaborative atorvastatin diabetes study cards was to assess the effectiveness of 10 mg of atorvastatin daily versus placebo in the primary prevention of cardiovascular disease in patients with type 2 diabetes.
The collaborative atorvastatin diabetes study cards is the first randomized controlled trial that assessed the effectiveness and safety of using atorvastatin in patients with type 2 diabetes. The collaborative atorvastatin diabetes study cards is a multicentre, randomized, placebocontrolled, doubleblind clinical trial of primary. Stroke prediction and stroke prevention with atorvastatin in. Based on the clinical cards data, the favourable cost effectiveness of atorvastatin 10 mg in patients with type 2 diabetes has been demonstrated in countries such as the uk and france. The overall safety profile of atorvastatin was similar between agegroups. The american diabetes association has recommended using statins a class of drug used to lower cholesterol levels for patients with type 2 diabetes.
The safety and tolerability of atorvastatin 10 mg in the. The clinical benefit of use of statins in patients with type 2 diabetes has been demonstrated in several randomized, controlled trials, including the cards clinical trial. Cards is designed to show if lowering cholesterol with. Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus colhoun hm, betteridge dj, durrington pn, et al. Objective to assess the representativeness of the heart protection study hps and the collaborative atorvastatin diabetes study cards for incident statin users. Patients with type 2 diabetes mellitus have a high risk of developing cardiovascular cv disease. The collaborative atorvastatin diabetes study cards is a multicentre, randomized, placebocontrolled, doubleblind clinical trial of primary prevention of cardiovascular disease in patients with type 2 diabetes.
Development of lifeexpectancy tables for people with type 2. The trial was stopped 2 years earlier than planned because of significant benefit at the second interim analysis. Atorvastatin is an inhibitor of 3hydroxy3methylglutarylcoenzyme a hmgcoa reductase. Safety of atorvastatin in the collaborative atorvastatin. Our lipitor side effects drug center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atovastatin diabetes study cards. Primary prevention of cardiovascular disease with atorvastatin in. Although the study was not powered for a direct comparison between the two statins, results of both planet i and ii suggest that atorvastatin and rosuvastatin have different renal profiles in patients with proteinuria, whereas the effects on lipids are similar, with a larger effect of rosuvastatin 40 mg than of atorvastatin 80 mg. Are statin trials in diabetes representative of realworld. The association of on study lowdensity lipoprotein ldl cholesterol and cv events by gender was evaluated in the combined studies and the impact of gender on adverse events in each study separately. A post hoc analysis of data from the collaborative atorvastatin diabetes study cards, a randomised, placebocontrolled trial of 2,838. An overview of cards collaborative atorvastatin diabetes. Mar 05, 2012 ironically, there is a very compelling clinical trial showing the value of one statin, lipitor atorvastatin, in type 2 diabetes the collaborative atorvastatin diabetes study known as cards.
Cost effectiveness of atorvastatin in patients with type 2. Design of the collaborative atorvastatin diabetes study cards in patients with type 2 diabetes article pdf available in diabetic medicine 193. Impact of female sex on lipid lowering, clinical outcomes. Collaborative atorvastatin diabetes study american college. The collaborative atorvastatin diabetes study cards is the first large primary prevention study to focus specifically on the role of a statin in patients aged 4075 years with type 2 diabetes.
1569 94 746 721 311 355 1263 1152 294 1458 102 1303 1481 1295 1056 350 708 1326 198 653 726 26 708 1060 990 1098 554 344 635 922 203 501